NASDAQ:RYTM

Rhythm Pharmaceuticals (RYTM) Stock Forecast, Price & News

$23.31

+0.08 (+0.34%)

(As of 09/22/2023 ET)

Compare

Today's Range: $22.86
▼
$23.79
50-Day Range: $16.78
▼
$27.80
52-Week Range: $15.50
▼
$34.99

Volume: 522,616 shs
Average Volume: 554,615 shs
Market Capitalization: $1.33 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $37.17

Rhythm Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 59.4% Upside
$37.17 Price Target
Short Interest: Bearish
21.34% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.80
Upright™ Environmental Score
News Sentiment: 0.80
Based on 8 Articles This Week
Insider Trading: Selling Shares
$503,100 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.24) to ($2.29) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

554th out of 968 stocks

Pharmaceutical Preparations Industry

248th out of 441 stocks

3.4

Analyst's Opinion

Consensus Rating
Rhythm Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $37.17, Rhythm Pharmaceuticals has a forecasted upside of 59.4% from its current price of $23.31.
Amount of Analyst Coverage
Rhythm Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
21.34% of the float of Rhythm Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Rhythm Pharmaceuticals has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Rhythm Pharmaceuticals has recently decreased by 2.83%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Rhythm Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Rhythm Pharmaceuticals does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Rhythm Pharmaceuticals has received a 63.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Anti-obesity medication (A08)", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for Rhythm Pharmaceuticals is -1.80.

2.7

News and Social Media Coverage

News Sentiment
Rhythm Pharmaceuticals has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Rhythm Pharmaceuticals this week, compared to 4 articles on an average week.
Search Interest
Only 6 people have searched for RYTM on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $503,100.00 in company stock.
Percentage Held by Insiders
Only 4.70% of the stock of Rhythm Pharmaceuticals is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($3.24) to ($2.29) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Rhythm Pharmaceuticals is -7.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Rhythm Pharmaceuticals is -7.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Rhythm Pharmaceuticals has a P/B Ratio of 4.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

RYTM Price History

30 days | 90 days | 365 days | Advanced Chart

RYTM Stock News Headlines

September 22, 2023 | finance.yahoo.com

Rhythm Pharmaceuticals Presents New Data at ESPE 2023

September 21, 2023 | msn.com

"Rhythm Bath" aims to help make performing arts more accessible to families with disabilities

September 24, 2023 | Behind the Markets (Ad)

AI Creates New Cancer Drug - In Just 30 Days!

On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...

September 20, 2023 | americanbankingnews.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Moderate Buy" by Analysts

September 19, 2023 | msn.com

Owensboro to host free Rhythm and Blues concert

September 19, 2023 | seekingalpha.com

Rhythm’s obesity therapy granted EU backing for orphan designation

September 19, 2023 | finance.yahoo.com

Companies Like Rhythm Pharmaceuticals (NASDAQ:RYTM) Are In A Position To Invest In Growth

September 19, 2023 | finance.yahoo.com

Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity

September 24, 2023 | Behind the Markets (Ad)

AI Creates New Cancer Drug - In Just 30 Days!

September 11, 2023 | finance.yahoo.com

EVP Jennifer Lee Sells 6,166 Shares of Rhythm Pharmaceuticals Inc (RYTM)

September 9, 2023 | mirror.co.uk

Headbangers: Rhythm Royale is far more than just another gimmicky pigeon game

September 9, 2023 | msn.com

Bristol Rhythm & Roots Reunion kicks off with many returning music artists

September 8, 2023 | finance.yahoo.com

Rhythm Pharmaceuticals Announces Update to September Conference Participation

September 6, 2023 | finanznachrichten.de

Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

September 6, 2023 | finance.yahoo.com

Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

August 24, 2023 | sg.style.yahoo.com

Director Shun Nakamura’s ‘Samba de Amigo: Party Central’ Channels TikTok In Rhythm Game Sequel

August 22, 2023 | msn.com

U.S. Air Force Rhythm in Blue Jazz Ensemble kicking off this week’s 8 Great Tuesdays

August 7, 2023 | finance.yahoo.com

Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France

August 4, 2023 | seekingalpha.com

Rhythm Pharmaceuticals: A Virtual Monopoly In Orphan Obesity Disorders

August 3, 2023 | msn.com

Morgan Stanley Reiterates Rhythm Pharmaceuticals (RYTM) Equal-Weight Recommendation

August 3, 2023 | msn.com

B of A Securities Upgrades Rhythm Pharmaceuticals (RYTM)

August 3, 2023 | finance.yahoo.com

Need To Know: Analysts Are Much More Bullish On Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenues

August 2, 2023 | seekingalpha.com

Rhythm Pharmaceuticals: Growth, Uncertainty, And A 'Sell' Recommendation

August 1, 2023 | marketwatch.com

Rhythm Pharmaceuticals Shares Jump After 2Q Revenue Tops Expectations

August 1, 2023 | msn.com

Rhythm Pharma surges on strong Q2 sales; BofA upgrades

August 1, 2023 | markets.businessinsider.com

Rhythm Pharmaceuticals (RYTM) Gets a Buy from Ladenburg Thalmann & Co.

August 1, 2023 | finance.yahoo.com

Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update

See More Headlines

Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RYTM Company Calendar

Last Earnings: 8/01/2023
Today: 9/23/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RYTM
CUSIP: N/A
CIK: 1649904
Web: www.rhythmtx.com
Phone: (857) 264-4280
Fax: 857-264-4299
Employees: 177
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $37.17
High Stock Price Forecast: $56.00
Low Stock Price Forecast: $27.00
Forecasted Upside/Downside: +59.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-181,120,000.00
Net Margins: -416.41%
Pretax Margin: -416.41%
Return on Equity: -76.93%
Return on Assets: -51.06%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.16
Quick Ratio: 6.02

Sales & Book Value

Annual Sales: $23.64 million
Price / Sales: 56.11
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.69 per share
Price / Book: 4.97

Miscellaneous

Outstanding Shares: 56,900,000
Free Float: 54,228,000
Market Cap: $1.33 billion
Optionable: Optionable
Beta: 1.62

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. David P. Meeker M.D. (Age 69)
Chairman, Pres & CEO
Comp: $1.17M

Mr. Hunter C. Smith M.B.A. (Age 54)
CFO & Treasurer
Comp: $692.2k

Mr. Joseph Shulman (Age 48)
Chief Technical Officer
Comp: $608.2k

Mr. Yann Mazabraud (Age 50)
Exec. VP & Head of International
Comp: $747.43k

Ms. Jennifer L. Chien (Age 48)
Exec. VP & Head of North America
Comp: $644.2k

Mr. Christopher German (Age 52)
Corp. Controller, Principal Accounting Officer & Exec. Director

Mr. David Connolly
Head of Investor Relations & Corp. Communications

Mr. Jim Flaherty
Sr. VP & Gen. Counsel

Ms. Sarah Ryan
VP of Sales & Marketing

Ms. Pamela J. Cramer (Age 49)
Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RYTM Stock - Frequently Asked Questions

Should I buy or sell Rhythm Pharmaceuticals stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RYTM shares.
View RYTM analyst ratings or view top-rated stocks.
What is Rhythm Pharmaceuticals' stock price forecast for 2023?: 6 analysts have issued 1-year target prices for Rhythm Pharmaceuticals' stock. Their RYTM share price forecasts range from $27.00 to $56.00. On average, they predict the company's stock price to reach $37.17 in the next year. This suggests a possible upside of 59.4% from the stock's current price.
View analysts price targets for RYTM or view top-rated stocks among Wall Street analysts.
How have RYTM shares performed in 2023?: Rhythm Pharmaceuticals' stock was trading at $29.12 on January 1st, 2023. Since then, RYTM stock has decreased by 20.0% and is now trading at $23.31.
View the best growth stocks for 2023 here.
When is Rhythm Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our RYTM earnings forecast.
How were Rhythm Pharmaceuticals' earnings last quarter?: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its earnings results on Tuesday, August, 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by $0.02. The firm earned $19.20 million during the quarter, compared to the consensus estimate of $15.03 million. Rhythm Pharmaceuticals had a negative net margin of 416.41% and a negative trailing twelve-month return on equity of 76.93%. The company's revenue was up 111.0% compared to the same quarter last year. During the same period last year, the business earned ($0.89) earnings per share.
What ETFs hold Rhythm Pharmaceuticals' stock?: ETFs with the largest weight of Rhythm Pharmaceuticals (NASDAQ:RYTM) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).BlackRock Future Health ETF (BMED).
What other stocks do shareholders of Rhythm Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

When did Rhythm Pharmaceuticals IPO?: (RYTM) raised $100 million in an IPO on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.
What is Rhythm Pharmaceuticals' stock symbol?: Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."
Who are Rhythm Pharmaceuticals' major shareholders?: Rhythm Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.01%), RA Capital Management L.P. (9.98%), Goldman Sachs Group Inc. (9.11%), State Street Corp (5.74%), Polar Capital Holdings Plc (3.95%) and VR Adviser LLC (1.92%). Insiders that own company stock include David P Meeker, Hunter C Smith, Jennifer Chien, Jennifer Kayden Lee, Joseph Shulman, Pamela J Cramer, Ra Capital Management, LP, William T Roberts and Yann Mazabraud.
View institutional ownership trends.
How do I buy shares of Rhythm Pharmaceuticals?: Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Rhythm Pharmaceuticals' stock price today?: One share of RYTM stock can currently be purchased for approximately $23.31.
How much money does Rhythm Pharmaceuticals make?: Rhythm Pharmaceuticals (NASDAQ:RYTM) has a market capitalization of $1.33 billion and generates $23.64 million in revenue each year. The company earns $-181,120,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis.
How many employees does Rhythm Pharmaceuticals have?: The company employs 177 workers across the globe.
How can I contact Rhythm Pharmaceuticals?: Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The official website for the company is www.rhythmtx.com. The company can be reached via phone at (857) 264-4280, via email at hannah.deresiewicz@sternir.com, or via fax at 857-264-4299.

This page (NASDAQ:RYTM) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial